

AUG. 4. 2004 3:12PM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL FAX CENTER

AUG 04 2004

OFFICIAL

**FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:
2501 US CNT

Applicants:
Constantin Agouridas, et al

Serial No.

10/075,635

Filing Date:
February 13, 2002

Title of Invention:
**2-Halogenated Derivatives Of 5-O-Desosmaninyl-Erythronolide A,
Their Preparation Process And Their Antibiotic Use**

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, at (703) 872-9306, on 8/4/04
Date of Deposit

Printed Name of Person Signing Certificate Maribel Mendez

Signature

Maribel Mendez

Total Number of Pages Sent: 7

Attorney: **Balaram Gupta**

Group Art Unit: **1624**
Examiner: **Coleman, Brenda Libby**

TO: Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit
account (18-1982) in the name of **Aventis Pharmaceuticals Inc.**

- | | |
|--|--|
| <input type="checkbox"/> Amendment, 37 CFR _____ | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input type="checkbox"/> Extension of Time Petition | <input type="checkbox"/> Other _____ |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <u>Amendment Pursuant to 37 C.F.R.</u>
<u>§1.121 and Reply Pursuant to 37</u>
<u>C.F.R. § 1.111 (6 pgs.)</u> |
| <input type="checkbox"/> Maintenance Fee Transmittal | |

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

RECEIVED
CENTRAL FAX CENTER

OFFICIAL

AUG 04 2004

PATENT

Docket No.: 2501 US CNT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
Constantin Agouridas, et al.

Examiner: Coleman, Brenda Libby

Art Unit: 1624

Serial No.: 10/075,635

Filed: February 13, 2002

TELEFAX CERTIFICATE

Title: 2-Halogenated Derivatives of 5-O-
Desosmaninyl-Erythronolide A, Their
Preparation Process and Their Antibiotic
UseI hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, at (703) 872-9306 on8/4/04
Date of transmission
Signature *W. Burke Meady*Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450**AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 AND REPLY
PURSUANT TO 37 C.F.R. § 1.111**

Sir:

This is a Rule 111 Amendment in the above-identified patent application in response to the Office Action, paper no. 3, dated, May 4, 2004, having a response due by, August 4, 2004. It is respectfully requested that the following amendments and remarks be entered in this case.

Request to Change Docket Number

Applicants respectfully submit that the docket number used in the instant case has been changed from "146.1327-CON" to "2501 US CNT". Accordingly, Applicants respectfully request the Examiner to enter this change into the record and to use the new docket number in all of the future Office Actions in this case.

2501 US CNT

-1 of 6-